Analysis on internal mechanism of zedoary turmeric in treatment of liver cancer based on pharmacodynamic substances and pharmacodynamic groups

Zedoary tumeric (Curcumae Rhizoma, Ezhu in Chinese) has a long history of application and has great potential in the treatment of liver cancer. The anti liver cancer effect of zedoary tumeric depends on the combined action of multiple pharmacodynamic substances. In order to clarify the specific mechanism of zedoary tumeric against liver cancer, this paper first analyzes the mechanism of its single pharmacodynamic substance against liver cancer, and then verifies the joint anti liver cancer mechanism of its "pharmacodynamic group". By searching the research on the anti hepatoma effect of active components of zedoary tumeric in recent years, we found that pharmacodynamic substances, including curcumol, zedoarondiol, curcumenol, curzerenone, curdione, curcumin, germacrone, β-elemene, can act on multi-target and multi-channel to play an anti hepatoma role. For example, curcumin can regulate miR, GLO1, CD133, VEGF, YAP, LIN28B, GPR81, HCAR-1, P53 and PI3K/Akt/mTOR, HSP70/TLR4 and NF-κB. Wnt/TGF/EMT, Nrf2/Keap1, JAK/STAT and other pathways play an anti hepatoma role. Network pharmacological analysis showed that the core targets of the "pharmacodynamic group" for anti-life cancer are AKT1, EGFR, MAPK8, etc, and the core pathways are neuroactive live receiver interaction, nitrogen metabolism, HIF-1 signaling pathway, etc. At the same time, by comparing and analyzing the relationship between the specific mechanisms of pharmacodynamic substance and "pharmacodynamic group", it is found that they have great reference significance in target, pathway, biological function, determination of core pharmacodynamic components, formation of core target protein interaction, in-depth research of single pharmacodynamic substance, increasing curative effect and so on. By analyzing the internal mechanism of zedoary tumeric pharmacodynamic substance and "pharmacodynamic group" in the treatment of liver cancer, this paper intends to provide some ideas and references for the deeper pharmacological research of zedoary tumeric and the relationship between pharmacodynamic substance and "pharmacodynamic group".     

改良大骨瓣联合软通道微创介入逐渐减压术治疗重型颅脑损伤的疗效分析

目的：探讨改良大骨瓣联合软通道微创介入逐渐减压术治疗重型颅脑损伤的疗效。方法方便选择自2009年12月—2014年11月该院收治的重型颅脑损伤病例70例,随机分为改良组和对照组2组,每组35例,改良组施行改良大骨瓣联合软通道微创介入逐渐减压术,对照组按标准大骨瓣开颅、硬脑膜一次性全切开,对比分析两组的并发症发生率及预后。结果改良组发生迟发性颅内血肿、大面积脑梗塞及弥漫性脑肿胀等并发症9例(25.7％,9/35),预后良好者23例(65.7％,23/35),对照组发生并发症19例(54.3％,19/35),预后良好者14例(40.0％,14/35),两组并发症发生率和预后差异具有统计学意义(P<0.05)。结论改良大骨瓣联合软通道微创介入逐渐减压术治疗重型颅脑损伤,效果良好,显著降低死亡率。     

All roads lead to Rome-a review of the potential mechanisms by which exerkines exhibit neuroprotective effects in Alzheimer’s disease

Age-related neurodegenerative disorders such as Alzheimer’s disease(AD)have become a critical public health issue due to the significantly extended human lifespan,leading to considerable economic and social burdens.Traditional therapies for AD such as medicine and surgery remain ineffective,impractical,and expensive.Many studies have shown that a variety of bioactive substances released by physical exercise(called“exerkines”)help to maintain and improve the normal functions of the brain in terms of cognition,emotion,and psychomotor coordination.Increasing evidence suggests that exerkines may exert beneficial effects in AD as well.This review summarizes the neuroprotective effects of exerkines in AD,focusing on the underlying molecular mechanism and the dynamic expression of exerkines after physical exercise.The findings described in this review will help direct research into novel targets for the treatment of AD and develop customized exercise therapy for individuals of different ages,genders,and health conditions.     

Angiotensin-(1–7)reducesα-synuclein aggregation by enhancing autophagic activity in Parkinson's disease

Abnormal accumulation ofα-synuclein contributes to the formation of Lewy bodies in the substantia nigra,which is considered the typical pathological hallmark of Parkinson's disease.Recent research indicates that angiotensin-(1-7)plays a crucial role in several neurodegenerative disorders,including Parkinson's disease,but the underlying mechanisms remain elusive.In this study,we used intraperitoneal administration of rotenone to male Sprague-Dawley rats for 4 weeks to establish a Parkinson's disease model.We investigated whether angiotensin-(1-7)is neuroprotective in this model by continuous administration of angiotensin-(1-7)into the right substantia nigra for 4 weeks.We found that angiotensin-(1-7)infusion relieved characteristic parkinsonian behaviors and reducedα-synuclein aggregation in the substantia nigra.Primary dopaminergic neurons were extracted from newborn Sprague-Dawley rat substantia nigras and treated with rotenone,angiotensin-(1-7),and/or the Mas receptor blocker A-779 for 24 hours.After binding to the Mas receptor,angiotensin-(1-7)attenuated apoptosis andα-synuclein aggregation in rotenone-treated cells.Primary dopaminergic neurons were also treated with angiotensin-(1-7)and/or the autophagy inhibitor 3-methyladenine for 24 hours.Angiotensin-(1-7)increasedα-synuclein removal and increased the autophagy of rotenone-treated cells.We conclude that angiotensin-(1-7)reducesα-synuclein aggregation by alleviating autophagy dysfunction in Parkinson's disease.Therefore,the angiotensin-(1-7)/Mas receptor axis plays an important role in the pathogenesis of Parkinson's disease and angiotensin-(1-7)has potential therapeutic value for Parkinson's disease.All experiments were approved by the Biological Research Ethics Committee of Nanjing First Hospital(approval No.DWSY-2000932)in January 2020.     

Ⅱ型糖原累积病的研究进展

Ⅱ型糖原累积病(glycogen storage disease typeⅡ,GSDⅡ)也称为酸性麦芽糖酶缺乏症或Pompe病,属于常染色体隐性遗传性疾病,是由于酸性α-糖苷酶的缺乏,导致溶酶体内的糖原分解障碍并大量贮积而致病。本文就Ⅱ型糖原累积病的流行病学、基因突变特征、诊断新方法和治疗方面的进展作一介绍。     

AN UNUSUAL BILATERAL VAGAL PARAGANGLIOMAS： ONE CASE STUDY

VAGAL paraganglioma VP)is an uncommonneoplasm originating from neural crest paragan-glion cells located along the vagus nerve,repre-senting less than5%of all paragangliomas of the head andneck.1Despite improvement in microsurgical techniques,management of…     

子宫肌瘤栓塞失败的分析

目的:旨在评估子宫肌瘤栓塞(UFE)治疗的疗效并分析U FE治疗失败的相关因素。设计:回顾性研究。机构:大学教学医院。患者:233例1997年11月至2004年2月连续接受U FE治疗的患者。干预:3位介入放射学专家应用355-500-μ聚乙烯醇微粒实施了子宫肌瘤栓塞术。主要观察指标:子宫切除率、子宫肌瘤切除率及重复U FE治疗率。结果:患者平均随访时间为13个月。总计有22例(9.4%)患者在U FE治疗后又接受了手术治疗,其中16例(6.9%)行子宫切除术,6例(2.6%)行子宫肌瘤切除术,包括3例患者进行了重复的U FE治疗后仍需手术治疗。U FE与后继治疗的平均间…     

肝脏干细胞的基础研究与应用前景

自20世纪90年代以来,全球已掀起了干细胞的研究热潮。干细胞(stemcell,SC)是一类既有自我更新能力,又有多向分化潜能的细胞,能产生表现型与基因型和自己完全相同的子细胞,同时还能分化为祖细胞,具有非常重要的理论研究意义和临床应用价值。其中,肝脏干细胞(liver stem cells,LS     

婴幼儿腹部切口裂开30例伴肠瘘7例原因分析

婴幼儿腹部切口裂开３０例伴肠瘘７例原因分析长治医学院附属医院（０４６０００）姬仁胜，南温博婴幼儿腹部手术后切口全层裂开常伴有内外露或脱出，是一种严重的术后并发症，死亡率可高达８～３０％以上，多年来曾遇婴幼儿切口全层裂开３０例，再缝合术后伴肠瘘７例，现就其原因，预防和治疗报道如下：临床资料本组３０例，男１９例，女１１例。年龄６个月～２岁。幽门肥厚１０例，肠套迭１２例，出血坏死性肠炎４例，阑尾炎４例。取右上腹直肌切口１０例，右下腹直肌切口２０例。本组３０例均用４号丝线连续缝合腹膜，其余层次均间断缝合。其中１１例缝合时有腹膜撕裂情况，裂开的诱因主要是切口感染、哭闹、腹胀、剧咳；营养不良等，裂开前均有血性渗出液。裂开时间最早为术后第３天，最晚为术后第１０天，术后４～８天多见。１８例全层减张缝合，１２例全层减张加分层缝合，减张缝合均用７号丝线。７例术后３～５天出现肠瘘，３例死亡，１例自动出院，３例行３次缝合痊愈。３年后发现腹壁切口疝４例，再缝合后愈合时间最早９天，最晚３６天，住院天数最短１８天，最长３个月。讨论一、腹部切口裂开的原因１．切口裂开与年龄的关系：婴幼儿切口裂开发生率高［１］，因婴幼儿腹部组织薄弱，切口张力     

糖尿病小切口胆囊切除术前非胰岛素准备的探讨

目的：探讨糖尿病小切口胆囊切除（MC）术前非胰岛素准备的可行性。方法：1996-1999年40例Ⅱ型糖尿病MC患据术前控制血糖的方法分成非胰岛素组和胰岛素组。比较其围手术期血糖、Na^ 、K^ 、二氧化碳结合力（CO2CP），观察MC术前非胰岛素准备对术后并发症的影响。结果：MC术前非胰岛素准备比胰岛素准备更能使糖尿病MC患术前血糖控制稳定，而不增加其术后并发症发生率。结论：非胰岛素准备是一简单、有效、易被接受的适合于糖尿病MC患术前控制血糖的方法。